請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59741
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曾賢忠 | |
dc.contributor.author | Tsung-Chih Tseng | en |
dc.contributor.author | 曾琮智 | zh_TW |
dc.date.accessioned | 2021-06-16T09:35:42Z | - |
dc.date.available | 2022-02-24 | |
dc.date.copyright | 2017-02-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-13 | |
dc.identifier.citation | Al-Hasani, R, Bruchas, MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011, 115(6): 1363-1381.
Amano, MT, Camara, NO. The immunomodulatory role of carbon monoxide during transplantation. Med Gas Res. 2013, 3(1): 1. Arreola, R, Becerril-Villanueva, E, Cruz-Fuentes, C, Velasco-Velazquez, MA, Garces-Alvarez, ME, Hurtado-Alvarado, G, Quintero-Fabian, S, Pavon, L. Immunomodulatory effects mediated by serotonin. J Immunol Res. 2015, 2015354957. Baganz, NL, Blakely, RD. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci. 2013, 4(1): 48-63. Bagavant, H, Deshmukh, US, Wang, H, Ly, T, Fu, SM. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol. 2006, 177(11): 8258-8265. Barnes, PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998, 94(6): 557-572. Beck, G, Brinkkoetter, P, Hanusch, C, Schulte, J, van Ackern, K, van der Woude, FJ, Yard, BA. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care. 2004, 8(6): 485-491. Bhargava, HN, Zhao, GM, House, RV, Thomas, PT. Effects of chronic administration of 7-benzylidene-7-dehydronaltrexone and naltriben on the antinociceptive actions of delta 1- and delta 2-opioid receptor agonists. Eur J Pharmacol. 1996, 311(2-3): 127-132. Bhat, R, Axtell, R, Mitra, A, Miranda, M, Lock, C, Tsien, RW, Steinman, L. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A. 2010, 107(6): 2580-2585. Bidlack, JM. Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol. 2000, 7(5): 719-723. Bogdan, C. Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 2015, 36(3): 161-178. Bogdan, C, Rollinghoff, M, Diefenbach, A. The role of nitric oxide in innate immunity. Immunol Rev. 2000, 17317-26. Bot, G, Blake, AD, Li, S, Reisine, T. Fentanyl and its analogs desensitize the cloned mu opioid receptor. J Pharmacol Exp Ther. 1998, 285(3): 1207-1218. Brandow, AM, Wandersee, NJ, Dasgupta, M, Hoffmann, RG, Hillery, CA, Stucky, CL, Panepinto, JA. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use. Br J Haematol. 2016, Brown, RE, Stevens, DR, Haas, HL. The physiology of brain histamine. Prog Neurobiol. 2001, 63(6): 637-672. Cabral, GA, Ferreira, GA, Jamerson, MJ. Endocannabinoids and the Immune System in Health and Disease. Handb Exp Pharmacol. 2015, 231185-211. Calder, PC, Yaqoob, P. Glutamine and the immune system. Amino Acids. 1999, 17(3): 227-241. Chavkin, C. The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology. 2011, 36(1): 369-370. Chhikara, M, Wang, S, Kern, SJ, Ferreyra, GA, Barb, JJ, Munson, PJ, Danner, RL. Carbon monoxide blocks lipopolysaccharide-induced gene expression by interfering with proximal TLR4 to NF-kappaB signal transduction in human monocytes. PLoS One. 2009, 4(12): e8139. Clatworthy, MR, Willcocks, L, Urban, B, Langhorne, J, Williams, TN, Peshu, N, Watkins, NA, Floto, RA, Smith, KG. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 2007, 104(17): 7169-7174. Cole, C, Thomas, S, Filak, H, Henson, PM, Lenz, LL. Nitric oxide increases susceptibility of Toll-like receptor-activated macrophages to spreading Listeria monocytogenes. Immunity. 2012, 36(5): 807-820. Coller, JK, Barratt, DT, Dahlen, K, Loennechen, MH, Somogyi, AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006, 80(6): 682-690. Connor, MA, Keir, MJ, Henderson, G. delta-opioid receptor mobilization of intracellular calcium in SH-SY5Y cells: lack of evidence for delta-receptor subtypes. Neuropharmacology. 1997, 36(1): 125-133. Coutinho, AE, Chapman, KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011, 335(1): 2-13. Dijkstra, G, Zandvoort, AJ, Kobold, AC, de Jager-Krikken, A, Heeringa, P, van Goor, H, van Dullemen, HM, Tervaert, JW, van de Loosdrecht, A, Moshage, H, Jansen, PL. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scand J Gastroenterol. 2002, 37(5): 546-554. Domercq, M, Vazquez-Villoldo, N, Matute, C. Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci. 2013, 749. Eltzschig, HK. Extracellular adenosine signaling in molecular medicine. J Mol Med (Berl). 2013, 91(2): 141-146. Ferone, D, van Hagen, PM, Semino, C, Dalm, VA, Barreca, A, Colao, A, Lamberts, SW, Minuto, F, Hofland, LJ. Somatostatin receptor distribution and function in immune system. Dig Liver Dis. 2004, 36 Suppl 1S68-77. Fuks, JM, Arrighi, RB, Weidner, JM, Kumar Mendu, S, Jin, Z, Wallin, RP, Rethi, B, Birnir, B, Barragan, A. GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog. 2012, 8(12): e1003051. Gan, X, Zhang, L, Solomon, GF, Bonavida, B. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain Behav Immun. 2002, 16(3): 227-246. Ganor, Y, Levite, M. The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. J Neural Transm (Vienna). 2014, 121(8): 983-1006. Gao, L, Xu, Z, Yin, Z, Chen, K, Wang, C, Zhang, H. Association of hydrogen sulfide with alterations of monocyte chemokine receptors, CCR2 and CX3CR1 in patients with coronary artery disease. Inflamm Res. 2015, 64(8): 627-635. Gaveriaux-Ruff, C, Filliol, D, Simonin, F, Matthes, HW, Kieffer, BL. Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther. 2001, 298(3): 1193-1198. Giles, BM, Boackle, SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013, 55(1-3): 10-21. Goodman, AJ, Le Bourdonnec, B, Dolle, RE. Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007, 2(11): 1552-1570. Guedes Marques, M, Cotovio, P, Ferrer, F, Silva, C, Botelho, C, Lopes, K, Maia, P, Carreira, A, Campos, M. Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? Clin Kidney J. 2013, 6(6): 590-594. Hansen, AM, Caspi, RR. Glutamate joins the ranks of immunomodulators. Nat Med. 2010, 16(8): 856-858. Harvey, PR, Gordon, C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs. 2013, 27(2): 85-95. Hasegawa, T, Suzuki, K, Kaneko, Y, Takeuchi, T. Proteinuria selectivity index as a prognostic biomarker in lupus nephritis. Lupus. 2016, Hasko, G, Linden, J, Cronstein, B, Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008, 7(9): 759-770. Hebb, AL, Poulin, JF, Roach, SP, Zacharko, RM, Drolet, G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry. 2005, 29(8): 1225-1238. Hoffman, RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol. 2004, 113(1): 4-13. Hoi, AY, Littlejohn, GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther. 2012, 12(10): 1399-1406. Hosoi, T, Nomura, Y. Functional role of acetylcholine in the immune system. Front Biosci. 2004, 92414-2419. House, RV, Thomas, PT, Kozak, JT, Bhargava, HN. Suppression of immune function by non-peptidic delta opioid receptor antagonists. Neurosci Lett. 1995, 198(2): 119-122. Jenny, M, Winkler, C, Spetea, M, Schennach, H, Schmidhammer, H, Fuchs, D. Non-peptidic delta-opioid receptor antagonists suppress mitogen-induced tryptophan degradation in peripheral blood mononuclear cells in vitro. Immunol Lett. 2008, 118(1): 82-87. Jiang, C, Foley, J, Clayton, N, Kissling, G, Jokinen, M, Herbert, R, Diaz, M. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol. 2007, 178(11): 7422-7431. Jin, Z, Mendu, SK, Birnir, B. GABA is an effective immunomodulatory molecule. Amino Acids. 2013, 45(1): 87-94. Johnson, RA, Johnson, FK. The effects of carbon monoxide as a neurotransmitter. Curr Opin Neurol. 2000, 13(6): 709-713. Jordan, BA, Devi, LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999, 399(6737): 697-700. Kaku, H, Cheng, KF, Al-Abed, Y, Rothstein, TL. A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol. 2014, 193(12): 5904-5913. Kamei, J, Iwamoto, Y, Suzuki, T, Misawa, M, Nagase, H, Kasuya, Y. Involvement of delta 1-opioid receptor antagonism in the antitussive effect of delta-opioid receptor antagonists. Eur J Pharmacol. 1994, 251(2-3): 291-294. Kamen, DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am. 2014, 40(3): 401-412, vii. Kasagi, S, Kawano, S, Okazaki, T, Honjo, T, Morinobu, A, Hatachi, S, Shimatani, K, Tanaka, Y, Minato, N, Kumagai, S. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol. 2010, 184(5): 2337-2347. Kasi, PM, Tawbi, HA, Oddis, CV, Kulkarni, HS. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012, 16(4): 231. Kasturi, S, Sammaritano, LR. Corticosteroids in Lupus. Rheum Dis Clin North Am. 2016, 42(1): 47-62, viii. Katoh, N, Soga, F, Nara, T, Tamagawa-Mineoka, R, Nin, M, Kotani, H, Masuda, K, Kishimoto, S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin Exp Immunol. 2006, 146(2): 354-361. Katsanos, GS, Anogeianaki, A, Orso, C, Tete, S, Salini, V, Antinolfi, PL, Sabatino, G. Impact of substance P on cellular immunity. J Biol Regul Homeost Agents. 2008, 22(2): 93-98. Kawashima, K, Fujii, T, Moriwaki, Y, Misawa, H. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci. 2012, 91(21-22): 1027-1032. Kelsey, JE, Verhaak, AM, Schierberl, KC. The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats. Behav Brain Res. 2015, 28316-21. Kohm, AP, Sanders, VM. Norepinephrine: a messenger from the brain to the immune system. Immunol Today. 2000, 21(11): 539-542. Koval, LM, Yu Lykhmus, O, Omelchenko, DM, Komisarenko, SV, Skok, MV. The role of alpha7 nicotinic acetylcholine receptors in B lymphocyte activation. Ukr Biokhim Zh (1999). 2009, 81(4): 5-11. Kronbichler, A, Frank, R, Kirschfink, M, Szilagyi, A, Csuka, D, Prohaszka, Z, Schratzberger, P, Lhotta, K, Mayer, G. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore). 2014, 93(26): e143. Kumar, V, Sharma, A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol. 2009, 616(1-3): 7-15. Kuo, JS, Chen, SF, Huang, HJ, Yang, CS, Tsai, PJ, Hsueh, CM. The involvement of glutamate in recall of the conditioned NK cell response. J Neuroimmunol. 2001, 118(2): 245-255. La Cava, A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010, 2(4): 575-582. Li, N, Ghia, JE, Wang, H, McClemens, J, Cote, F, Suehiro, Y, Mallet, J, Khan, WI. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011, 178(2): 662-671. Li, X, Kimberly, RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014, 18(3): 335-350. Liang, X, Liu, R, Chen, C, Ji, F, Li, T. Opioid System Modulates the Immune Function: A Review. Transl Perioper Pain Med. 2016, 1(1): 5-13. Liao, X, Reihl, AM, Luo, XM. Breakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic Cells. J Immunol Res. 2016, 20166269157. Linner, KM, Stickney, BJ, Quist, HE, Sharp, BM, Portoghese, PS. The delta1-opioid receptor antagonist, 7-(benzospiroindanyl)naltrexone [correction of 7-benzylspiroindanylnaltrexone], prolongs renal allograft survival in a rat model. Eur J Pharmacol. 1998, 354(1): R3-5. Linzke, N, Schumacher, A, Woidacki, K, Croy, BA, Zenclussen, AC. Carbon monoxide promotes proliferation of uterine natural killer cells and remodeling of spiral arteries in pregnant hypertensive heme oxygenase-1 mutant mice. Hypertension. 2014, 63(3): 580-588. Lood, C, Tyden, H, Gullstrand, B, Klint, C, Wenglen, C, Nielsen, CT, Heegaard, NH, Jonsen, A, Kahn, R, Bengtsson, AA. Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus. PLoS One. 2015, 10(4): e0125109. Lorton, D, Bellinger, DL. Molecular mechanisms underlying beta-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int J Mol Sci. 2015, 16(3): 5635-5665. Lutfy, K, Cowan, A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004, 2(4): 395-402. Mackay, M, Stanevsky, A, Wang, T, Aranow, C, Li, M, Koenig, S, Ravetch, JV, Diamond, B. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 2006, 203(9): 2157-2164. Mackern-Oberti, JP, Obreque, J, Mendez, GP, Llanos, C, Kalergis, AM. Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus. Clin Exp Immunol. 2015, 182(1): 1-13. Mackie, K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008, 20 Suppl 110-14. Maggi, CA. The mammalian tachykinin receptors. Gen Pharmacol. 1995, 26(5): 911-944. Mague, SD, Pliakas, AM, Todtenkopf, MS, Tomasiewicz, HC, Zhang, Y, Stevens, WC, Jr., Jones, RM, Portoghese, PS, Carlezon, WA, Jr. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003, 305(1): 323-330. Mak, A, Kow, NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014, 2014419029. Marshall-Gradisnik, S, Huth, T, Chacko, A, Johnston, S, Smith, P, Staines, D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. Appl Clin Genet. 2016, 939-47. Mashaghi, A, Marmalidou, A, Tehrani, M, Grace, PM, Pothoulakis, C, Dana, R. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016, McKenna, F, McLaughlin, PJ, Lewis, BJ, Sibbring, GC, Cummerson, JA, Bowen-Jones, D, Moots, RJ. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol. 2002, 132(1-2): 34-40. Mikulak, J, Bozzo, L, Roberto, A, Pontarini, E, Tentorio, P, Hudspeth, K, Lugli, E, Mavilio, D. Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. J Immunol. 2014, 193(6): 2792-2800. Milan-Lobo, L, Enquist, J, van Rijn, RM, Whistler, JL. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS One. 2013, 8(3): e58362. Mirandola, P, Gobbi, G, Sponzilli, I, Pambianco, M, Malinverno, C, Cacchioli, A, De Panfilis, G, Vitale, M. Exogenous hydrogen sulfide induces functional inhibition and cell death of cytotoxic lymphocytes subsets. J Cell Physiol. 2007, 213(3): 826-833. Mok, CC, Lau, CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003, 56(7): 481-490. Mosca, M, Tani, C, Carli, L, Bombardieri, S. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. 2011, 29(5 Suppl 68): S126-129. Mossner, R, Lesch, KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998, 12(4): 249-271. Moy, KV, Ma, JD, Best, BM, Atayee, RS. Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain. J Anal Toxicol. 2014, 38(1): 1-7. Neubert, JK, Rossi, HL, Pogar, J, Jenkins, AC, Caudle, RM. Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors. Behav Brain Funct. 2007, 349. Nijnik, A, Ferry, H, Lewis, G, Rapsomaniki, E, Leung, JC, Daser, A, Lambe, T, Goodnow, CC, Cornall, RJ. Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. Int Immunol. 2006, 18(7): 1127-1137. Nowling, TK, Gilkeson, GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011, 13(6): 250. O'Connor, TM, O'Connell, J, O'Brien, DI, Goode, T, Bredin, CP, Shanahan, F. The role of substance P in inflammatory disease. J Cell Physiol. 2004, 201(2): 167-180. Oh, GS, Pae, HO, Lee, BS, Kim, BN, Kim, JM, Kim, HR, Jeon, SB, Jeon, WK, Chae, HJ, Chung, HT. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med. 2006, 41(1): 106-119. Olde Nordkamp, MJ, Koeleman, BP, Meyaard, L. Do inhibitory immune receptors play a role in the etiology of autoimmune disease? Clin Immunol. 2014, 150(1): 31-42. Ostensen, M, Villiger, PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2001, 10(3): 135-139. Pacheco, R, Contreras, F, Zouali, M. The dopaminergic system in autoimmune diseases. Front Immunol. 2014, 5117. Pacheco, R, Gallart, T, Lluis, C, Franco, R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol. 2007, 185(1-2): 9-19. Pandey, R, Mousawy, K, Nagarkatti, M, Nagarkatti, P. Endocannabinoids and immune regulation. Pharmacol Res. 2009, 60(2): 85-92. Panelius, J, Meri, S. Complement system in dermatological diseases - fire under the skin. Front Med (Lausanne). 2015, 23. Perry, D, Sang, A, Yin, Y, Zheng, YY, Morel, L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011, 2011271694. Podolska, MJ, Biermann, MH, Maueroder, C, Hahn, J, Herrmann, M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015, 8161-171. Pomorska, DK, Gach, K, Janecka, A. Immunomodulatory effects of endogenous and synthetic peptides activating opioid receptors. Mini Rev Med Chem. 2014, 14(14): 1148-1155. Pongratz, G, Straub, RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014, 16(6): 504. Postal, M, Costallat, LT, Appenzeller, S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol. 2012, 2012578641. Pradhan, AA, Befort, K, Nozaki, C, Gaveriaux-Ruff, C, Kieffer, BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci. 2011, 32(10): 581-590. Prado, C, Contreras, F, Gonzalez, H, Diaz, P, Elgueta, D, Barrientos, M, Herrada, AA, Lladser, A, Bernales, S, Pacheco, R. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol. 2012, 188(7): 3062-3070. Qiu, Y, Peng, Y, Wang, J. Immunoregulatory role of neurotransmitters. Adv Neuroimmunol. 1996, 6(3): 223-231. Qiu, YH, Peng, YP, Jiang, JL, Wang, JJ. Effect of acetylcholine on in vitro IL-2 production and NK cell cytotoxicity of rats. Lymphology. 2004, 37(1): 31-38. Ratkay, LG, Zhang, L, Tonzetich, J, Waterfield, JD. Complete Freund's adjuvant induces an earlier and more severe arthritis in MRL-lpr mice. J Immunol. 1993, 151(9): 5081-5087. Reynolds, JA, Ray, DW, Zeef, LA, O'Neill, T, Bruce, IN, Alexander, MY. The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus. J Interferon Cytokine Res. 2014, 34(5): 404-412. Rocha, SM, Pires, J, Esteves, M, Graca, B, Bernardino, L. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. Front Cell Neurosci. 2014, 8120. Rozenfeld, R, Devi, LA. Receptor heteromerization and drug discovery. Trends Pharmacol Sci. 2010, 31(3): 124-130. Sabahi, R, Anolik, JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs. 2006, 66(15): 1933-1948. Saitoh, A, Yoshikawa, Y, Onodera, K, Kamei, J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl). 2005, 182(3): 327-334. Salamone, G, Lombardi, G, Gori, S, Nahmod, K, Jancic, C, Amaral, MM, Vermeulen, M, Espanol, A, Sales, ME, Geffner, J. Cholinergic modulation of dendritic cell function. J Neuroimmunol. 2011, 236(1-2): 47-56. Scanzano, A, Cosentino, M. Adrenergic regulation of innate immunity: a review. Front Pharmacol. 2015, 6171. Shippenberg, TS, Chefer, VI, Thompson, AC. Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry. 2009, 65(2): 169-174. Sobczak, M, Salaga, M, Storr, MA, Fichna, J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014, 49(1): 24-45. Sofuoglu, M, Portoghese, PS, Takemori, AE. 7-Benzylidenenaltrexone (BNTX): a selective delta 1 opioid receptor antagonist in the mouse spinal cord. Life Sci. 1993, 52(8): 769-775. Soyka, M. Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol. 2014, 17(4): 675-684. Soyka, M, Rosner, S. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. Curr Drug Abuse Rev. 2008, 1(3): 280-291. St-Pierre, S, Jiang, W, Roy, P, Champigny, C, LeBlanc, E, Morley, BJ, Hao, J, Simard, AR. Nicotinic Acetylcholine Receptors Modulate Bone Marrow-Derived Pro-Inflammatory Monocyte Production and Survival. PLoS One. 2016, 11(2): e0150230. Stachlewitz, RF, Li, X, Smith, S, Bunzendahl, H, Graves, LM, Thurman, RG. Glycine inhibits growth of T lymphocytes by an IL-2-independent mechanism. J Immunol. 2000, 164(1): 176-182. Sthoeger, Z, Sharabi, A, Mozes, E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun. 2014, 5460-71. Stuckey, DJ, Anthony, DC, Lowe, JP, Miller, J, Palm, WM, Styles, P, Perry, VH, Blamire, AM, Sibson, NR. Detection of the inhibitory neurotransmitter GABA in macrophages by magnetic resonance spectroscopy. J Leukoc Biol. 2005, 78(2): 393-400. Sturgill, JL, Mathews, J, Scherle, P, Conrad, DH. Glutamate signaling through the kainate receptor enhances human immunoglobulin production. J Neuroimmunol. 2011, 233(1-2): 80-89. Suarez-Fueyo, A, Rojas, JM, Cariaga, AE, Garcia, E, Steiner, BH, Barber, DF, Puri, KD, Carrera, AC. Inhibition of PI3Kdelta reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol. 2014, 193(2): 544-554. Takai, T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002, 2(8): 580-592. Takenaka, MC, Araujo, LP, Maricato, JT, Nascimento, VM, Guereschi, MG, Rezende, RM, Quintana, FJ, Basso, AS. Norepinephrine Controls Effector T Cell Differentiation through beta2-Adrenergic Receptor-Mediated Inhibition of NF-kappaB and AP-1 in Dendritic Cells. J Immunol. 2016, 196(2): 637-644. Tan, BH, Wong, PT, Bian, JS. Hydrogen sulfide: a novel signaling molecule in the central nervous system. Neurochem Int. 2010, 56(1): 3-10. Tanaka, T, Narazaki, M, Kishimoto, T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011, 585(23): 3699-3709. Tanasescu, R, Gran, B, Constantinescu, CS. The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Amino Acids. 2013, 45(1): 95-112. Tanguay, S, Killion, JJ. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res. 1994, 13(4): 259-263. Tardif, V, Riquelme, SA, Remy, S, Carreno, LJ, Cortes, CM, Simon, T, Hill, M, Louvet, C, Riedel, CA, Blancou, P, Bach, JM, Chauveau, C, Bueno, SM, Anegon, I, Kalergis, AM. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. Eur J Immunol. 2013, 43(11): 2832-2844. ten Bokum, AM, Hofland, LJ, van Hagen, PM. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw. 2000, 11(2): 161-176. Thamer, M, Hernan, MA, Zhang, Y, Cotter, D, Petri, M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009, 36(3): 560-564. Tian, J, Lu, Y, Zhang, H, Chau, CH, Dang, HN, Kaufman, DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol. 2004, 173(8): 5298-5304. Townsend, DWt, Brown, DR. Pharmacological characterization of a 7-benzylidenenaltrexone-preferring opioid receptor in porcine ileal submucosa. Br J Pharmacol. 2003, 140(4): 691-700. Tselios, K, Gladman, DD, Su, J, Urowitz, MB. Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus. Lupus. 2016, 25(5): 532-535. Tsuchiya, H, Haga, S, Takahashi, Y, Kano, T, Ishizaka, Y, Mimori, A. Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford). 2014, 53(7): 1219-1228. Van den Eynden, J, Ali, SS, Horwood, N, Carmans, S, Brone, B, Hellings, N, Steels, P, Harvey, RJ, Rigo, JM. Glycine and glycine receptor signalling in non-neuronal cells. Front Mol Neurosci. 2009, 29. van Hagen, PM, Dalm, VA, Staal, F, Hofland, LJ. The role of cortistatin in the human immune system. Mol Cell Endocrinol. 2008, 286(1-2): 141-147. van Rijn, RM, Whistler, JL. The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry. 2009, 66(8): 777-784. Vanderah, TW. Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain. 2010, 26 Suppl 10S10-15. Veelken, R, Vogel, EM, Hilgers, K, Amann, K, Hartner, A, Sass, G, Neuhuber, W, Tiegs, G. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol. 2008, 19(7): 1371-1378. Verinaud, L, Issayama, LK, Zanucoli, F, de Carvalho, AC, da Costa, TA, Di Gangi, R, Bonfanti, AP, Ferreira, IT, de Oliveira, AL, Machado, DR, Thome, R. Nitric oxide plays a key role in the suppressive activity of tolerogenic dendritic cells. Cell Mol Immunol. 2015, 12(3): 384-386. Vukelic, M, Qing, X, Redecha, P, Koo, G, Salmon, JE. Cholinergic receptors modulate immune complex-induced inflammation in vitro and in vivo. J Immunol. 2013, 191(4): 1800-1807. Wang, M, Zhu, J, Pan, Y, Dong, J, Zhang, L, Zhang, X, Zhang, L. Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson's disease. J Neurosci Res. 2015, 93(3): 487-494. White, CA, Pone, EJ, Lam, T, Tat, C, Hayama, KL, Li, G, Zan, H, Casali, P. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014, 193(12): 5933-5950. Wiesik-Szewczyk, E, Lacki, JK, Feleszko, W, Olesinska, M. Target therapies in systemic lupus erythematosus: current state of the art. Mini Rev Med Chem. 2010, 10(10): 956-965. Wink, DA, Hines, HB, Cheng, RY, Switzer, CH, Flores-Santana, W, Vitek, MP, Ridnour, LA, Colton, CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011, 89(6): 873-891. Winkelmann, RR, Kim, GK, Del Rosso, JQ. Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol. 2013, 6(1): 27-38. Wohleb, ES, McKim, DB, Sheridan, JF, Godbout, JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front Neurosci. 2014, 8447. Wu, Y, He, S, Bai, B, Zhang, L, Xue, L, Lin, Z, Yang, X, Zhu, F, He, P, Tang, W, Zuo, J. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. Cell Mol Immunol. 2016, 13(3): 379-390. Wu, YW, Tang, W, Zuo, JP. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015, 36(12): 1395-1407. Xiu, F, Stanojcic, M, Jeschke, MG. Norepinephrine inhibits macrophage migration by decreasing CCR2 expression. PLoS One. 2013, 8(7): e69167. Yan, D, Weisshaar, M, Lamb, K, Chung, HK, Lin, MZ, Plemper, RK. Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Biochemistry. 2015a, 54(36): 5589-5604. Yan, SX, Deng, XM, Wang, QT, Sun, XJ, Wei, W. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Acta Pharmacol Sin. 2015b, 36(11): 1367-1376. Yang, R, Qu, C, Zhou, Y, Konkel, JE, Shi, S, Liu, Y, Chen, C, Liu, S, Liu, D, Chen, Y, Zandi, E, Chen, W, Zhou, Y, Shi, S. Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis. Immunity. 2015, 43(2): 251-263. Yazdany, J, Davis, J. The role of CD40 ligand in systemic lupus erythematosus. Lupus. 2004, 13(5): 377-380. Yildirim-Toruner, C, Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011, 127(2): 303-312; quiz 313-304. Zampeli, E, Tiligada, E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009, 157(1): 24-33. Zhang, L, Yang, N, Wang, S, Huang, B, Li, F, Tan, H, Liang, Y, Chen, M, Li, Y, Yu, X. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus. 2011, 20(7): 667-677. Zhao, J, Lopez, AL, Erichsen, D, Herek, S, Cotter, RL, Curthoys, NP, Zheng, J. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem. 2004, 88(1): 169-180. Zhong, Z, Wheeler, MD, Li, X, Froh, M, Schemmer, P, Yin, M, Bunzendaul, H, Bradford, B, Lemasters, JJ. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care. 2003, 6(2): 229-240. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59741 | - |
dc.description.abstract | 7-Benzylidenenaltrexone (BNTX)是一種δ1型鴉片類受體(δ1 opioid receptor,簡稱DOR1)的拮抗劑。先前的研究指出BNTX能抑制免疫細胞增殖和存活,但是它的作用機制不明,也未曾用於治療免疫疾病。本研究目的以MRL/lpr紅斑性狼瘡鼠驗證BNTX是否有療效,並探討其作用機制。我們在小鼠17週齡已呈現狼瘡腎炎時分別自腹腔給予2, 5或10 mg/kg/day BNTX 14天做療效評估。結果顯示,BNTX能夠改善老鼠的臉部蝴蝶斑、掉髮與關節腫等外觀狀況,甚至使鬍鬚再長出。與對照組小鼠比較,BNTX各劑量均能有效降低脾臟與淋巴結腫大,且不影響體重。進一步分析發現BNTX顯著減少脾臟和骨髓中分泌IgG、IgM和dsDNA-IgG及-IgM自體免疫抗體的漿細胞數目和血清抗體效價。最重要的是BNTX能夠顯著改善狼瘡腎炎,包括:降低蛋白尿、減少IgM免疫複合體沉積腎絲球和腎小管間質、維護腎絲球型態與大小和緩解腎纖維化。在作用機制方面,初步發現BNTX能使FcγRIIB表達上升,這與FcγRIIB能透過與免疫複合體傳遞訊息抑制B細胞增殖和促進B細胞凋亡,減少免疫複合體在腎臟沉積吻合。有趣的是,BNTX這些作用並不須透過δ1型鴉片類受體,因為DOR1基因敲落並不影響FcγRIIB上升。而且,廣效型δ型鴉片類受體拮抗劑naltrindole和全鴉片類受體拮抗劑naloxone均不影響FcγRIIB表達。這樣的結果顯示BNTX對於B細胞的抑制機制具特異性,值得進一步研究找出作用蛋白。總結,本研究提供多項證據顯示BNTX對紅斑性狼瘡鼠之腎炎具有療效,而減少自體免疫漿細胞與促進FcγRIIB表達誘導細胞凋亡有關。由於目前紅斑性狼瘡治療仍以類固醇為主,副作用大。近年來,採用專一性抗體選擇性去除B細胞以降低免疫複合體生成,已證明能緩解狼瘡腎炎並延長病人壽命。因此,以低劑量BNTX減少B細胞,若機制明確,應有臨床應用價值。 | zh_TW |
dc.description.abstract | 7-Benzylidenenaltrexone (BNTX) is a δ1 opioid receptor antagonist. BNTX is known to be immuosuppressive but its mechanism remains elusive, thereby restricting its development for clinical use. In this study, we sought to investigate the potential therapeutic effects in MRL/lpr lupus mice. We treated mice of 17 weeks old when nephritis was evident by intraperitoneal injection of BNTX at 2, 5 and 10 mg/kg/day respectively for 14 days. A five-parameter scoring system was used to evaluate and monitor disease activities of lupus before and after treatment with vehicle or BNTX. We found that the signs and symptoms of lupus mice improved most significantly in including butterfly-like rashes, alopecia, sparse whiskers and arthritis after BNTX treatment. We further found that BNTX at various doses all significantly reduced the degree of splenomegaly and lymphadenopathy. The body weight of BNTX-treated mice remained unaltered, suggesting a safe dose range of BNTX in our experiments. Moreover, BNTX treatment dramatically decreased the numbers of IgG- and IgM-antibody-secreting cells (ASCs) and more importantly the anti-dsDNA-IgG and -IgM ASCs in the spleen and bone marrow, respectively. Concomitantly, serum titers of autoantibodies also decreased in BNTX-treated mice but not in control mice. Importantly, BNTX ameliorated lupus nephritis, including proteinuria, immune complex deposition in glomeruli and interstitial fibrosis. To investigate the mechanisms of BNTX in B cells, we found that BNTX could up-regulate the expression levels of FcγRIIB, which is a crucial negative regulator of B cells. Because FcγRIIB can trigger apoptosis of B cells via immune complexes, this explains the BNTX-mediated reduction of ASCs in MRL/lpr mice. Interestingly, knockdown of DOR1 gene did not affect FcγRIIB expression induced by BNTX. In contrast, natrindole, a non-selective δ opioid receptor antagonist, and naloxone, a pan-opioid receptor antagonist, did not affect the expression level of FcγRIIB. These results suggest a unique role of BNTX in the upregulation of FcγRIIB but its underlying mechanisms require further investigation. Because recent studies suggest a selective depletion of B cells via antibodies and histone deacetylation inhibitors can alleviate lupus nephritis, BNTX may be an additional promising candidate using this strategy. Further studies to elucidate the molecular mechanisms of BNTX in immune cells shall facilitate its clinical application for the treatment of systemic lupus erythematosus. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:35:42Z (GMT). No. of bitstreams: 1 ntu-106-R03443027-1.pdf: 4054050 bytes, checksum: bdd302824d3d3c25618f4ecd7f50da70 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 中文摘要 iii ABSTRACT iv CONTENTS vi LIST of FIGURES viii LIST of TABLE ix LIST of ABBREVIATIONS x Chapter 1 Introduction 1 1.1 Neurotransmitters and immune system 2 1.1.1 Amino acids 2 1.1.2 Monoamines 4 1.1.3 Acetylcholine 8 1.1.4 Gasotransmitters 9 1.1.5 Purines 11 1.1.6 Peptides 12 1.1.7 Others 15 1.2 Opioids and opioid receptor 16 1.2.1 Opioid receptor and downstream signaling 16 1.2.2 Interaction between opioid receptors and proteins 18 1.2.3 Agonist and Antagonist of opioid receptors 19 1.3 Systemic lupus erythematosus (SLE) 21 1.3.1 Etiology of SLE 21 1.3.2 Therapies of SLE 23 1.3.3 Neurotransmitter and Systemic lupus erythematosus 29 1.3.4 Role of inhibitory receptors in SLE 33 1.4 7-Benzylidenenaltrexone maleate (BNTX) 35 1.5 Motivation 36 Chapter 2 Materials and Methods 37 2.1 Reagents 38 2.2 Cell line 38 2.3 Mice 38 2.4 Scoring system 39 2.5 Mouse Serum and urine collection 39 2.6 Preparation of the murine splenocytes and bone marrow cells for ELISPOT assay 39 2.6.1 Splenocytes 40 2.6.2 Bone marrow cells 40 2.7 Enzyme-linked immunosorbent spot (ELISPOT) assay 40 2.8 Enzyme-linked immunosorbent assay (ELISA) for immunoglobulins and anti-double-strand DNA (anti-dsDNA) 42 2.8.1 Measurement of serum IgG and IgM titers 42 2.8.2 Measurement of anti-dsDNA IgG and IgM in serum 43 2.9 Urine analysis 43 2.10 Histopathology 43 2.10.1 Masson trichrome 43 2.10.2 Immunohistochemistry (IHC) 44 2.11 Western blotting 45 2.12 Statistics 46 Chapter 3 Results 47 3.1 BNTX ameliorated the lupus symptoms and reduced the disease activities in MRL/lpr mice 48 3.2 BNTX reduced splenomegaly and lymphadenopathy in MRL/lpr mice 49 3.3 Decreased immunoglobulin- and anti-dsDNA-secreting cells in the spleen and bone marrow of MRL/lpr mice after BNTX treatment 49 3.6 BNTX reduced deposition of IgM immune complex in the glomeruli and in the inter-tubular space of kidneys 51 3.7 BNTX improved interstitial and glomerular fibrosis in kidneys of MRL/lpr mice 52 3.8 BNTX up-regulated FcγRIIB expression independent of DOR1 53 Chapter 4 Discussion 54 4.1 BNTX treatment alleviated lupus nephritis in MRL/lpr mice 55 4.2 Glucocorticoids and rituximab in the treatment of patients with SLE 56 4.3 BNTX up-regulated FcγRIIB expression independent of δ1 opioid receptor 58 Figures 59 Table 92 References 101 | |
dc.language.iso | en | |
dc.title | BNTX用於治療全身性紅斑性狼瘡之研究 | zh_TW |
dc.title | A study of BNTX in the treatment for systemic lupus erythematosus | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林琬琬,符文美,葉嘉新,忻凌偉 | |
dc.subject.keyword | 全身性紅斑性狼瘡,免疫抑制,FcγRIIB,BNTX,δ1型鴉片類受體拮抗劑, | zh_TW |
dc.subject.keyword | Systemic lupus erythematosus,Immunosuppression,FcγRIIB,7-Benzylidenenaltrexone (BNTX),δ1 opioid receptor antagonist, | en |
dc.relation.page | 118 | |
dc.identifier.doi | 10.6342/NTU201700356 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-02-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.96 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。